Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib + bevacizumab + temozolomide for recurrent or progressive high-grade glioma
ChiCTR2600132610Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebreltinib, bevacizumab and temozolomide in glioma, sponsored by Tangdu Hospital. Primary endpoint: Overall survival time. Started Sep 2026; status: recruiting.
02
Drugs
vebreltinibbevacizumabtemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2600132610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132610.